RecruitingNCT05517811
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Studying Pediatric hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Colorado, Denver
- Principal Investigator
- Ana Gleisner, MDUniversity of Colorado, Denver
- Intervention
- TEG indices(diagnostic_test)
- Enrollment
- 400 target
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2022 – 2028
Study locations (1)
- University of Colorado Denver, Aurora, Colorado, United States
Collaborators
Haemonetics Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05517811 on ClinicalTrials.govOther trials for Pediatric hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07295340Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC DetectionWest China Hospital
- RECRUITINGNANCT06050200TANGO-LIVER Three Arm Nuclear Growth Observation in Liver SurgeryMedical University of Warsaw
- RECRUITINGPHASE1NCT04715191Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsBaylor College of Medicine
- RECRUITINGNCT06669377TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.Zhongda Hospital
- ACTIVE NOT RECRUITINGNANCT07214363The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver CancersNational Taiwan University Hospital
- RECRUITINGNANCT05738980Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3Beijing Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05120271BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid TumorsSotio Biotech Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT04377932Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsBaylor College of Medicine